GSK-J1 free acid | CAS#1373422-53-7 | JMJD3 inhibitor

MedKoo Cat#: 556375 | Name: GSK-J1 free acid

Description:

WARNING: This product is for research use only, not for human or veterinary use.

GSK-J1 is a potent JMJD3 inhibitor. MJD3 inhibition by GSK-J1 significantly alleviated the severity of inflammation in LPS-induced mastitis. GSK-J1 treatment led to the recruitment of histone 3 lysine 27 trimethylation (H3K27me3), an inhibitory chromatin mark, in vitro. GSK-J1 treatment directly interfered with the transcription of inflammatory-related genes by H3K27me3 modification of their promoters. JMJD3 depletion or inhibition by GSK-J1 decreased the expression of toll-like receptor 4 and negated downstream NF-κB proinflammatory signaling and subsequently reduced LPS-stimulated upregulation of Tnfa, Il1b, and Il6.

Chemical Structure

GSK-J1 free acid

CAS#1373422-53-7 (free acid)

Theoretical Analysis

MedKoo Cat#: 556375

Name: GSK-J1 free acid

CAS#: 1373422-53-7 (free acid)

Chemical Formula: C22H23N5O2

Exact Mass: 389.1852

Molecular Weight: 389.46

Elemental Analysis: C, 67.85; H, 5.95; N, 17.98; O, 8.22

Price and Availability

Size	Price	Availability
25mg	USD 450.00	2 Weeks
50mg	USD 750.00	2 Weeks
100mg	USD 1,250.00	2 Weeks
1g	USD 4,250.00	2 Weeks

Bulk Inquiry

Buy Now

Add to Cart

Related CAS #

1797832-71-3 (soidum) 1373422-53-7 (free acid)

Synonym

GSK-J1 free acid; GSK-J1; GSK J1; GSKJ1;

IUPAC/Chemical Name

3-((2-(pyridin-2-yl)-6-(1,2,4,5-tetrahydro-3H-benzo[d]azepin-3-yl)pyrimidin-4-yl)amino)propanoic acid

InChi Key

AVZCPICCWKMZDT-UHFFFAOYSA-N

InChi Code

InChI=1S/C22H23N5O2/c28-21(29)8-12-24-19-15-20(26-22(25-19)18-7-3-4-11-23-18)27-13-9-16-5-1-2-6-17(16)10-14-27/h1-7,11,15H,8-10,12-14H2,(H,28,29)(H,24,25,26)

SMILES Code

OC(CCNC1=CC(N2CCC3=C(CC2)C=CC=C3)=NC(C4=CC=CC=N4)=N1)=O

Appearance

To be determined

Purity

>98% (or refer to the Certificate of Analysis)

Shipping Condition

Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition

Dry, dark and at 0 -4 C for short term (days to weeks) or -20 C for long term(months to years).

Solubility

To be determined

Shelf Life

>2 years if stored properly

Drug Formulation

To be determined

Stock Solution Storage

0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code

2934.99.9001

More Info

Instruction

View handling instruction

Preparing Stock Solutions

The following data is based on the product molecular weight 389.46 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
1 mM	1.15 mL	5.76 mL	11.51 mL
5 mM	0.23 mL	1.15 mL	2.3 mL
10 mM	0.12 mL	0.58 mL	1.15 mL
50 mM	0.02 mL	0.12 mL	0.23 mL

1: Wang C, Hu B, Yang Y, Wang Y, Qin J, Wen X, Li Y, Li H, Wang Y, Wang J, Liu Y. Structural simulation and selective inhibitor discovery study for histone demethylases KDM4E/6B from a computational perspective. Comput Biol Chem. 2024 Jun;110:108072. doi: 10.1016/j.compbiolchem.2024.108072. Epub 2024 Apr 12. PMID: 38636391. 2: Schniewind I, Besso MJ, Klicker S, Schwarz FM, Hadiwikarta WW, Richter S, Löck S, Linge A, Krause M, Dubrovska A, Baumann M, Kurth I, Peitzsch C. Epigenetic Targeting to Overcome Radioresistance in Head and Neck Cancer. Cancers (Basel). 2024 Feb 9;16(4):730. doi: 10.3390/cancers16040730. PMID: 38398123; PMCID: PMC10886471. 3: Yang B, Liu W, Li M, Mo J. GSK-J1-loaded, hyaluronic acid-decorated metal- organic frameworks for the treatment of ovarian cancer. Front Pharmacol. 2022 Nov 7;13:1023719. doi: 10.3389/fphar.2022.1023719. PMID: 36419626; PMCID: PMC9676248. 4: Leng XY, Yang J, Fan H, Chen QY, Cheng BJ, He HX, Gao F, Zhu F, Yu T, Liu YJ. JMJD3/H3K27me3 epigenetic modification regulates Th17/Treg cell differentiation in ulcerative colitis. Int Immunopharmacol. 2022 Sep;110:109000. doi: 10.1016/j.intimp.2022.109000. Epub 2022 Jun 28. PMID: 35777266. 5: Cheng F, Li H, Liu J, Yan F, Chen Y, Hu H. EZH2 regulates the balance between osteoclast and osteoblast differentiation to inhibit arthritis-induced bone destruction. Genes Immun. 2022 Jun;23(3-4):141-148. doi: 10.1038/s41435-022-00174-8. Epub 2022 May 17. PMID: 35581496. 6: Wang JJ, Wang X, Xian YE, Chen ZQ, Sun YP, Fu YW, Wu ZK, Li PX, Zhou ES, Yang ZT. The JMJD3 histone demethylase inhibitor GSK-J1 ameliorates lipopolysaccharide-induced inflammation in a mastitis model. J Biol Chem. 2022 Jun;298(6):102017. doi: 10.1016/j.jbc.2022.102017. Epub 2022 May 6. PMID: 35526564; PMCID: PMC9168612. 7: Meng Y, Zhang T, Zheng R, Ding S, Yang J, Liu R, Jiang Y, Jiang W. Depletion of Demethylase KDM6 Enhances Early Neuroectoderm Commitment of Human PSCs. Front Cell Dev Biol. 2021 Sep 8;9:702462. doi: 10.3389/fcell.2021.702462. PMID: 34568320; PMCID: PMC8455897. 8: Zhang W, Cheng J, Diao P, Wang D, Zhang W, Jiang H, Wang Y. Therapeutically targeting head and neck squamous cell carcinoma through synergistic inhibition of LSD1 and JMJD3 by TCP and GSK-J1. Br J Cancer. 2020 Feb;122(4):528-538. doi: 10.1038/s41416-019-0680-6. Epub 2019 Dec 18. PMID: 31848446; PMCID: PMC7028736. 9: Lin J, Jiang Y, Liu D, Dai X, Wang M, Dai Y. Early secreted antigenic target of 6-kDa of Mycobacterium tuberculosis induces transition of macrophages into epithelioid macrophages by downregulating iNOS / NO-mediated H3K27 trimethylation in macrophages. Mol Immunol. 2020 Jan;117:189-200. doi: 10.1016/j.molimm.2019.11.013. Epub 2019 Dec 6. PMID: 31816492. 10: Whatley KCL, Padalino G, Whiteland H, Geyer KK, Hulme BJ, Chalmers IW, Forde-Thomas J, Ferla S, Brancale A, Hoffmann KF. The repositioning of epigenetic probes/inhibitors identifies new anti-schistosomal lead compounds and chemotherapeutic targets. PLoS Negl Trop Dis. 2019 Nov 15;13(11):e0007693. doi: 10.1371/journal.pntd.0007693. PMID: 31730617; PMCID: PMC6881072. 11: Zhang Y, Lou C, Xu Y, Li J, Qian S, Li F, Kang J. Screening of inhibitors against histone demethylation jumonji domain-containing protein 3 by capillary electrophoresis. J Chromatogr A. 2020 Feb 22;1613:460625. doi: 10.1016/j.chroma.2019.460625. Epub 2019 Oct 19. PMID: 31668999. 12: Vogel FCE, Bordag N, Zügner E, Trajkovic-Arsic M, Chauvistré H, Shannan B, Váraljai R, Horn S, Magnes C, Thomas Siveke J, Schadendorf D, Roesch A. Targeting the H3K4 Demethylase KDM5B Reprograms the Metabolome and Phenotype of Melanoma Cells. J Invest Dermatol. 2019 Dec;139(12):2506-2516.e10. doi: 10.1016/j.jid.2019.06.124. Epub 2019 Jun 21. PMID: 31229500. 13: Murillo-Rodríguez E, Arankowsky-Sandoval G, Barros JA, Rocha NB, Yamamoto T, Machado S, Budde H, Telles-Correia D, Monteiro D, Cid L, Veras AB. Sleep and Neurochemical Modulation by DZNep and GSK-J1: Potential Link With Histone Methylation Status. Front Neurosci. 2019 Mar 15;13:237. doi: 10.3389/fnins.2019.00237. PMID: 30930741; PMCID: PMC6428769. 14: Hong F, Zhao M, Zhang L, Feng L. Inhibition of Ezh2 In Vitro and the Decline of Ezh2 in Developing Midbrain Promote Dopaminergic Neurons Differentiation Through Modifying H3K27me3. Stem Cells Dev. 2019 May 15;28(10):649-658. doi: 10.1089/scd.2018.0258. Epub 2019 Apr 25. PMID: 30887911. 15: Arifuzzaman S, Rahman MS, Pang MG. Research update and opportunity of non- hormonal male contraception: Histone demethylase KDM5B-based targeting. Pharmacol Res. 2019 Mar;141:1-20. doi: 10.1016/j.phrs.2018.12.003. Epub 2018 Dec 11. PMID: 30550955. 16: Raeisossadati R, Móvio MI, Walter LT, Takada SH, Del Debbio CB, Kihara AH. Small Molecule GSK-J1 Affects Differentiation of Specific Neuronal Subtypes in Developing Rat Retina. Mol Neurobiol. 2019 Mar;56(3):1972-1983. doi: 10.1007/s12035-018-1197-3. Epub 2018 Jul 7. PMID: 29981055. 17: Johansson C, Velupillai S, Tumber A, Szykowska A, Hookway ES, Nowak RP, Strain-Damerell C, Gileadi C, Philpott M, Burgess-Brown N, Wu N, Kopec J, Nuzzi A, Steuber H, Egner U, Badock V, Munro S, LaThangue NB, Westaway S, Brown J, Athanasou N, Prinjha R, Brennan PE, Oppermann U. Structural analysis of human KDM5B guides histone demethylase inhibitor development. Nat Chem Biol. 2016 Jul;12(7):539-45. doi: 10.1038/nchembio.2087. Epub 2016 May 23. PMID: 27214403. 18: Hu J, Wang X, Chen L, Huang M, Tang W, Zuo J, Liu YC, Shi Z, Liu R, Shen J, Xiong B. Design and discovery of new pyrimidine coupled nitrogen aromatic rings as chelating groups of JMJD3 inhibitors. Bioorg Med Chem Lett. 2016 Feb 1;26(3):721-725. doi: 10.1016/j.bmcl.2016.01.006. Epub 2016 Jan 7. PMID: 26776360. 19: Horton JR, Engstrom A, Zoeller EL, Liu X, Shanks JR, Zhang X, Johns MA, Vertino PM, Fu H, Cheng X. Characterization of a Linked Jumonji Domain of the KDM5/JARID1 Family of Histone H3 Lysine 4 Demethylases. J Biol Chem. 2016 Feb 5;291(6):2631-46. doi: 10.1074/jbc.M115.698449. Epub 2015 Dec 8. PMID: 26645689; PMCID: PMC4742734. 20: Yang D, Okamura H, Teramachi J, Haneji T. Histone demethylase Utx regulates differentiation and mineralization in osteoblasts. J Cell Biochem. 2015 Nov;116(11):2628-36. doi: 10.1002/jcb.25210. PMID: 25920016.